Significance, detection and markers of disseminated breast cancer cells

Endocrine-Related Cancer

Volumn 13, Issue 4, 2006, Pages 1033-1067

  Lacroix, Marc ^a,b  

^a JULES BORDET INSTITUTE   (Belgium)

^b InTextoResearch ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; MUCIN 1; PACLITAXEL; TRASTUZUMAB; TREFOIL PEPTIDE; TUMOR MARKER;

BONE MARROW CELL; BREAST CANCER; CANCER CELL; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CELL SPECIFICITY; CELL VIABILITY; CLINICAL TRIAL; GENE LOCUS; HUMAN; MYOEPITHELIUM CELL; NUCLEIC ACID ANALYSIS; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM CIRCULATING CELLS; NEOPLASM PROTEINS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33846815517     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-06-0001     Document Type: Review

References (273)

1. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW & Ellis IO 2005 High-throughput protein expression analysis using tissue microarray technology of a large well-characterized series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analysis. International Journal of Cancer 116 340-350.
2. Abdul-Rasool S, Kidson SH, Panieri E, Dent D, Pillay K & Hanekom GS 2006 An evaluation of molecular markers for improved detection of breast cancer metastases in sentinel nodes. Journal of Clinical Pathology 59 289-297.
3. Aguirre-Ghiso JA 2006 The problem of cancer dormancy: understanding the basic mechanisms and identifying therapeutic opportunities. Cell Cycle 5 1740-1743.
4. Aihara T, Fujiwara Y, Ooka M, Sakita I, Tamaki Y & Monden M 1999 Mammaglobin B as a novel marker for detection of breast cancer micrometastases in axillary lymph nodes by reverse transcription-polymerase chain reaction. Breast Cancer Research and Treatment 58 137-140.
5. Albertson DG, Collins C, McCormick F & Gray JW 2003 Chromosome aberrations in solid tumors. Nature Genetics 34 369-376.
6. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ & Clarke MF 2003 Prospective identification of tumorigenic breast cancer cells. PNAS 100 3983-3988.
7. Alix-Panabières C, Brouillet JP, Fabbro M, Yssel H, Rousset T, Maudelonde T, Choquet-Kastylevsky G & Vendrell JP 2005 Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. Journal of Immunological Methods 299 177-188.
8. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Kochli O et al. 2004 Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Research 64 8534-8540.
9. Austrup F, Uciechowski P, Eder C, Bockmann B, Suchy B, Driesel G, Jackel S, Kusiak I, Grill HJ & Giesing M 2000 Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients. British Journal of Cancer 83 1664-1673.
10. Backus J, Laughlin T, Wang Y, Belly R, White R, Baden J, Min CJ, Mannie A, Tafra L, Atkins D et al. 2005 Identification and characterization of optimal gene expression markers for detection of breast cancer metastasis. Journal of Molecular Diagnosis 7 327-336.
11. Baker MK, Mikhitarian K, Osta W, Callahan K, Hoda R, Brescia F, Kneuper-Hall R, Mitas M, Cole DJ & Gillanders WE 2003 Molecular detection of breast cancer cells in the peripheral blood of advanced-stage breast cancer patients using multimarker real-time reverse transcription-polymerase chain reaction and a novel porous barrier density gradient centrifugation technology. Clinical Cancer Research 9 4865-4871.
12. Becker RM, Darrow C, Zimonjic DB, Popescu NC, Watson MA & Fleming TP 1998 Identification of mammaglobin B, a novel member of the uteroglobin gene family. Genomics 54 70-78.
13. Ben Hsieh H, Marrinucci D, Bethel K, Curry DN, Humphrey M, Krivacic RT, Kroener J, Kroener L, Ladanyi A, Lazarus N et al. 2006 High speed detection of circulating tumor cells. Biosensors and Bioelectronics 21 1893-1899.
14. Benoy IH, Salgado R, Elst H, Van Dam P, Weyler J, Van Marck E, Scharpe S, Vermeulen PB & Dirix LY 2005 Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically nonmetastatic breast cancer. Breast Cancer Research 7 R210-R219.
15. Benoy IH, Elst H, Philips M, Wuyts H, Van Dam P, Scharpe S, Van Marck E, Vermeulen PB & Dirix LY 2006 Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. British Journal of Cancer 94 672-680.
16. Berois N, Varangot M, Aizen B, Estrugo R, Zarantonelli L, Fernandez P, Krygier G, Simonet F, Barrios E, Muse I et al. 2000 Molecular detection of cancer cells in bone marrow and peripheral blood of patients with operable breast cancer. Comparison of CK19, MUC1 and CEA using RT-PCR. European Journal of Cancer 36 717-723.
17. Bertucci F, Houlgatte R, Benziane A, Granjeaud S, Adelaide J, Tagett R, Loriod B, Jacquemier J, Viens P, Jordan B et al. 2000 Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Human Molecular Genetics 9 2981-2999.
18. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, Adelaïde J, Debono S, Houvenaeghel G, Maraninchi D, Viens P et al. 2006 Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancer. Cancer Research 66 4636-4644.
19. Bieche I, Girault I, Sabourin JC, Tozlu S, Driouch K, Vidaud M & Lidereau R 2003 Prognostic value of maspin mRNA expression in ER alpha-positive postmenopausal breast carcinomas. British Journal of Cancer 88 863-870.
20. Bleiweiss IJ, Nagi CS & Jaffer S 2006 Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma. Journal of Clinical Oncology 24 2013-2018.
21. Bosma AJ, Weigelt B, Lambrechts AC, Verhagen OJ, Pruntel R, Hart AA, Rodenhuis S & van't Veer LJ 2002 Detection of circulating breast tumor cells by differential expression of marker genes. Clinical Cancer Research 8 1871-1877.
22. Bostick PJ, Chatterjee S, Chi DD, Huynh KT, Giuliano AE, Cote R & Hoon DS 1998 Limitations of specific reverse transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. Journal of Clinical Oncology 16 2632-2640.
23. Bozionellou V, Mavroudis D, Perraki M, Papadopoulos S, Apostolaki S, Stathopoulos E, Stathopoulou A, Lianidou E & Georgoulias V 2004 Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood of patients with breast cancer. Clinical Cancer Research 10 8185-8194.
24. Braun S & Pantel K 1999 Biological characteristics of micrometastatic cancer cells in bone marrow. Cancer and Metastasis Reviews 18 75-90.
25. Braun S & Naume B 2005 Circulating and disseminated tumor cells. Journal of Clinical Oncology 23 1623-1626.
26. Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F, Sommer H & Pantel K 2000a Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. Journal of Clinical Oncology 18 80-86.
27. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G et al. 2000b Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. New England Journal of Medicine 342 525-533.
28. Braun S, Cevatli BS, Assemi C, Janni W, Kentenich CR, Schindlbeck C, Rjosk D & Hepp F 2001a Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. Journal of Clinical Oncology 19 1468-1475.
29. Braun S, Cevatli BS, Assemi C, Janni W, Kentenich CR, Schindlbeck C, Rjosk D & Hepp F 2001b ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Research 61 1890-1895.
30. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G et al. 2005 A pooled analysis of bone marrow micrometastasis in breast cancer. New England Journal of Medicine 353 793-802.
31. Brenton JD, Carey LA, Ahmed AA & Caldas C 2005 Molecular classification and molecular forecasting of breast cancer: ready for clinical application? Journal of Clinical Oncology 23 7350-7360.
32. Brown NM, Stenzel TT, Friedman PN, Henslee J, Huper G & Marks JR 2006 Evaluation of expression based markers for the detection of breast cancer cells. Breast Cancer Research and Treatment 97 41-47.
33. Bussey KJ, Chin K, Lababidi S, Reimers M, Reinhold WC, Kuo WL, Gwadry F, Ajay W, Kouros-Mehr H, Fridlyand J et al. 2006 Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Molecular Cancer Therapeutics 5 853-867.
34. Callagy G, Cattaneo E, Daigo Y, Happerfield L, Bobrow LG, Pharoah PD & Caldas C 2003 Molecular classification of breast carcinomas using tissue microarrays. Diagnostic Molecular Pathology 12 27-34.
35. Campbell MJ, Scott J, Maecker HT, Park JW & Esserman LJ 2005 Immune dysfunction and micrometastases in women with breast cancer. Breast Cancer Research and Treatment 91 163-171.
36. Carter D, Douglass JF, Cornellison CD, Retter MW, Johnson JC, Bennington AA, Fleming TP, Reed SG, Houghton RL, Diamond DL et al. 2002 Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer. Biochemistry 41 6714-6722.
37. Chambers AF, Groom AC & MacDonald IC 2002 Dissemination and growth of cancer cells in metastatic sites. Nature Reviews Cancer 2 563-572.
38. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adélaïde J, Cervera N, Xerri L, Jacquemier J, Birnbaum D & Bertucci F 2006 Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25 2273-2284.
39. Ciborowski P & Finn OJ 2002 Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis. Clinical and Experimental Metastasis 19 339-345.
40. Clark JW, Snell L, Shiu RP, Orr FW, Maitre N, Vary CP, Cole DJ & Watson PH 1999 The potential role for prolactin-inducible protein (PIP) as a marker of human breast cancer micrometastasis. British Journal of Cancer 81 1002-1008.
41. Colpitts TL, Billing-Medel P, Friedman P, Granados EN, Hayden M, Hodges S, Menhart N, Roberts L, Russell J & Stroupe SD 2001 Mammaglobin is found in breast tissue as a complex with BU101. Biochemistry 40 11048-11059.
42. Colpitts TL, Billing P, Granados E, Hayden M, Hodges S, Roberts L, Russell J, Friedman P & Stroupe S 2002 Identification and immunohistochemical characterization of a mucin-like glycoprotein expressed in early stage breast carcinoma. Tumor Biology 23 263-278.
43. Corradini P, Voena C, Astolfi M, Delloro S, Pilotti S, Arrigoni G, Bregni M, Pileri A & Gianni AM 2001 Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer. Annals of Oncology 12 1693-1698.
44. Cote RJ, Rosen PP, Lesser ML, Old LJ & Osborne MP 1991 Prediction of early relapse in patients with operable breast cancer by detection of occult bone micrometastases. Journal of Clinical Oncology 9 1749-1756.
45. Cote RJ, Peterson HF, Chaiwun B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Gusterson B & Neville AM 1999 Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 354 896-900.
46. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW et al. 2004 Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New England Journal of Medicine 351 781-791.
47. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC et al. 2005a Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. Journal of Clinical Oncology 23 1420-1430.
48. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Doyle GV, Allard WJ, Terstappen LW & Hayes DF 2005b Presence of circulating tumor cells (CTC) in metastatic breast cancer (MBC) predicts rapid progression and poor prognosis. Journal of Clinical Oncology 23 Supplement 524.
49. de Graaf H, Maelandsmo GM, Ruud P, Forus A, Oyjord T, Fodstad O & Hovig E 1997 Ectopic expression of target genes may represent an inherent limitation of RT-PCR assays used for micrometastasis detection: studies on the epithelial glycoprotein gene EGP-2. International Journal of Cancer 72 191-196.
50. Dell'orto P, Olivia Biasi M, Del Curto B, Zurrida S, Galimberti V & Viale G 2006 Assessing the status of axillary sentinel lymph nodes of breast carcinoma patients by a real-time quantitative RT-PCR assay for mammaglobin 1 mRNA. Breast Cancer Research and Treatment 98 185-190.
51. de Longueville F, Lacroix M, Barbuto AM, Bertholet V, Gallo D, Larsimont D, Marcq L, Zammatteo N, Boffe S, Leclercq G et al. 2005 Molecular characterization of breast cancer cell lines by a low-density microarray. International Journal of Oncology 27 881-892.
52. De Luca A, Pignata S, Casamassimi A, D'Antonio A, Gridelli C, Rossi A, Cremona F, Parisi V, De Matteis A & Normanno N 2000 Detection of circulating tumor cells in carcinoma patients by a novel epidermal growth factor receptor reverse transcription-PCR assay. Clinical Cancer Research 6 1439-1444.
53. Drageset V, Nesland JM, Erikstein B, Skovlund E, Sommer H, Anker G, Wist E, Lundgren S, Bergh J & Kvalheim G 2006 Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy. International Journal of Cancer 118 2877-2881.
54. Eltahir EM, Mallinson DS, Birnie GD, Hagan C, George WD & Purushotham AD 1998 Putative markers for the detection of breast carcinoma cells in blood. British Journal of Cancer 77 1203-1207.
55. Emens LA, Reilly RT & Jaffee EM 2005 Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. Endocrine-Related Cancer 12 1-17.
56. Fabisiewicz A, Kulik J, Kober P, Brewczynska E, Pienkowski T & Siedlecki JA 2004 Detection of circulating breast cancer cells in peripheral blood by a two-marker reverse transcriptase-polymerase chain reaction assay. Acta Biochimica Polonica 51 747-755.
57. Fehm T, Sagalowsky A, Clifford E, Beitsch P, Saboorian H, Euhus D, Meng S, Morrison L, Tucker T, Lane N et al. 2002 Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clinical Cancer Research 8 2073-2084.
58. Fehm T, Becker S, Pergola-Becker G, Kramer B, Gruber I, Sotlar K, Kurek R, Wallwiener D & Solomayer E 2004 Influence of tumor biological factors on tumor cell dissemination in primary breast cancer. Anticancer Research 24 4211-4216.
59. Felsher DW 2006 Tumor dormancy: death and resurrection of cancer as seen through transgenic mouse models. Cell Cycle 5 1808-1811.
60. Ferrucci PF, Rabascio C, Mazzetta C, Cocorocchio E, Agazzi A, Vanazzi A, Cinieri S, Peccatori FA, Paolucci M, Bertolini F et al. 2004 Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer. Clinical Cancer Research 10 6039-6046.
61. Fetsch PA, Cowan KH, Weng DE, Freifield A, Filie AC & Abati A 2000 Detection of circulating tumor cells and micrometastases in stage II, III and IV breast cancer patients utilizing cytology and immunohistochemistry. Diagnostic Cytopatholgy 22 323-328.
62. Fiegl H, Millinger S, Müller-Holzner E, Marth C, Ensinger C, Berger A, Klocker H, Goebel G & Widschwendter M 2005 Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Research 65 1141-1145.
63. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER & Wolmark N 2002 Twenty-five year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. New England Journal of Medicine 347 567-575.
64. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M & Akslen LA 2003 Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. Journal of the National Cancer Institute 95 1482-1485.
65. Fox SB, Leek RD, Bliss J, Mansi JL, Gusterson B, Gatter KC & Harris AL 1997 Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. Journal of the National Cancer Institute 89 1044-1049.
66. Freire T, Berois N, Sonora C, Varangot M, Barrios E & Osinaga E 2006 UDP-N-acetyl-D-galactosamine:polypeptide N- acetylgalactosaminyltransferase 6 (ppGalNAc-T6) mRNA as a potential new marker for detection of bone marrow-disseminated breast cancer cells. International Journal of Cancer 119 1383-1388.
67. Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, Segraves R, Dairkee S, Tokuyasu T, Ljung BM, Jain AN et al. 2006 Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 6 96.
68. Gaforio JJ, Serrano MJ, Sanchez-Rovira P, Sirvent A, Delgado-Rodriguez M, Campos M, de la Torre N, Algarra I, Duenas R & Lozano A 2003 Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. International Journal of Cancer 107 984-990.
69. Galang CK, Muller WJ, Foos G, Oshima RG & Hauser CA 2004 Changes in the expression of many Ets family transcription factors and of potential target genes in normal mammary tissue and tumors. Journal of Biological Chemistry 279 11281-11292.
70. Gangnus R, Langer S, Breit E, Pantel K & Speicher MR 2004 Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clinical Cancer Research 10 3457-3464.
71. Gebauer G, Fehm T, Merkle E, Beck EP, Lang N & Jager W 2001 Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. Journal of Clinical Oncology 19 3669-3674.
72. Gerber B, Krause A, Muller H, Richter D, Reimer T, Makovitzky J, Herrnring C, Jeschke U, Kundt G & Friese K 2001 Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. Journal of Clinical Oncology 19 960-971.
73. Ghadersohi A & Sood AK 2001 Prostate epithelium-derived Ets transcription factor mRNA is overexpressed in human breast tumors and is a candidate breast tumor marker and a breast tumor antigen. Clinical Cancer Research 7 2731-2738.
74. Giatromanolaki A, Koukourakis MI, Kakolyris S, Mavroudis D, Kouroussis C, Mavroudi C, Perraki M, Sivridis E & Georgoulias V 2004 Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse. International Journal of Cancer 108 620-627.
75. Gilbey AM, Burnett D, Coleman RE & Holen I 2004 The detection of circulating breast cancer cells. Journal of Clinical Pathology 57 903-911.
76. Gillanders WE, Mikhitarian K, Hebert R, Mauldin PD, Palesch Y, Walters C, Urist MM, Mann GB, Doherty G, Herrmann VM et al. 2004 Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis. Annals of Surgery 239 828-837.
77. Glinsky GV, Berezovska O & Glinskii AB 2005 Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. Journal of Clinical Investigation 115 1503-1521.
78. Goeminne JC, Guillaume T, Salmon M, Machiels JP, D'Hondt V & Symann M 1999 Unreliability of carcinoembryonic antigen (CEA) reverse transcriptase-polymerase chain reaction (RT-PCR) in detecting contaminating breast cancer cells in peripheral blood stem cells due to induction of CEA by growth factors. Bone Marrow Transplantation 24 769-775.
79. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B & Senn HJ 2003 Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. Journal of Clinical Oncology 21 3357-3365.
80. Gradilone A, Gazzaniga P, Silvestri I, Gandini O, Trasatti L, Lauro S, Frati L & Agliano AM 2003 Detection of CK19, CK20 and EGFR mRNAs in peripheral blood of carcinoma patients: correlation with clinical stage of disease. Oncology Reports 10 217-222.
81. Gray JW 2003 Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. Cancer Cell 4 4-6.
82. Grunewald K, Haun M, Urbanek M, Fiegl M, Muller-Holzner E, Gunsilius E, Dunser M, Marth C & Gastl G 2000 Mammaglobin gene expression: a superior marker of breast cancer cells in peripheral blood in comparison to epidermalgrowth-factor receptor and cytokeratin-19. Laboratory Investigations 80 1071-1077.
83. Guan XF, Hamedani MK, Adeyinka A, Walker C, Kemp A, Murphy LC, Watson PH & Leygue E 2003 Relationship between mammaglobin expression and estrogen receptor status in breast tumors. Endocrine 21 245-250.
84. Gunawardane RN, Sgroi DC, Wrobel CN, Koh E, Daley GQ & Brugge JS 2005 Novel role for PDEF in epithelial cell migration and invasion. Cancer Research 65 11572-11580.
85. Haagensen DE Jr Dilley WG, Mazoujian G & Wells SA Jr 1990 Review of GCDFP-15. An apocrine marker protein. Annals of the New York Academy of Sciences 586 161-173.
86. Hager G, Cacsire-Castillo Tong D, Schiebel I, Rezniczek GA, Watrowski R, Speiser P & Zeillinger R 2005 The use of a panel of monoclonal antibodies to enrich circulating breast cancer cells facilitates their detection. Gynecological Oncology 98 211-216.
87. Han JH, Kang Y, Shin HC, Kim HS, Kang YM, Kim YB & Oh SY 2003 Mammaglobin expression in lymph nodes is an important marker of metastatic breast carcinoma. Archives of Pathology and Laboratory Medicine 127 1330-1334.
88. Harigopal M, Berger AJ, Camp RL, Rimm DL & Kluger HM 2005 Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer. Clinical Cancer Research 11 4083-4089.
89. Hawes D, Neville AM & Cote RJ 2001 Detection of occult metastasis in patients with breast cancer. Seminars in Surgery and Oncology 20 312-318.
90. Hayes DF, Walker TM, Singh B, Vitetta ES, Uhr JW, Gross S, Rao C, Doyle GV & Terstappen LW 2002 Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. International Journal of Oncology 21 1111-1117.
91. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV & Terstappen LWWM 2006 Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clinical Cancer Research 12 4218-4224.
92. Hedblom E & Kirkness EF 1997 A novel class of GABAA receptor subunit in tissue of the reproductive system. Journal of Biological Chemistry 272 15346-15350.
93. Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, Kau SW, Fornage B, Sahin A, Broglio K et al. 2005 Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. Journal of Clinical Oncology 23 9304-9311.
94. Hill RP 2006 Identifying cancer stem cells in solid tumors: case not proven. Cancer Research 66 1891-1895.
95. Hoffmann W 2005 Trefoil factors TFF (trefoil factor family) peptide-triggered signals promoting mucosal restitution. Cellular and Molecular Life Sciences 62 2932-2938.
96. Houghton RL, Dillon DC, Molesh DA, Zehentner BK, Xu J, Jiang J, Schmidt C, Frudakis A, Repasky E, Maltez Filho A et al. 2001 Transcriptional complementarity in breast cancer: application to detection of circulating tumor cells. Molecular Diagnosis 6 79-91.
97. Hu XC & Chow LWC 2001 Detection of circulating breast cancer cells with multiple marker RT-PCR assay. Anticancer Research 21 421-424.
98. Hu XC, Loo WT & Chow LW 2003 Surgery related shedding of breast cancer cells as determined by RT-PCR assay. Journal of Surgical Oncology 82 228-232.
99. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L et al. 2006 The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7 96.
100. Hubé F, Mutawe M, Leygue E & Myal Y 2004 Human small breast epithelium mucin: the promise of a new breast tumor biomarker. DNA and Cell Biology 23 842-849.
101. Hughes SJ, Xi L, Raja S, Gooding W, Cole DJ, Gillanders WE, Mikhitarian K, McCarty K, Silver S, Ching J et al. 2006 A rapid, fully automated, molecular-based assay accurately analyzes sentinel lymph nodes for the presence of metastatic breast cancer. Annals of Surgery 243 389-398.
102. Indraccolo S, Favaro E & Amadori A 2006 Dormant tumors awaken by a short-term angiogenic burst: the spike hypothesis. Cell Cycle 5 1751-1755.
103. International (Ludwig) Breast Cancer Study Group 1990 Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 335 1565-1568.
104. Jäger D & Knuth A 2005 Antibodies and vaccines - hope or illusion. The Breast 14 631-635.
105. Jäger D, Stockert E, Gure AO, Scanlan MJ, Karbach J, Jager E, Knuth A, Old LJ & Chen YT 2001 Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Research 61 2055-2061.
106. Jäger D, Unkelbach M, Frei C, Bert F, Scanlan MJ, Jäger E, Old LJ, Chen YT & Knuth A 2002 Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum. Cancer Immunity 2 5.
107. Jäger D, Karbach J, Pauligk C, Seil I, Frei C, Chen YT, Old LJ, Knuth A & Jäger E 2005 Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes. Cancer Immunity 5 11.
108. Jain RK 1990 Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Research 50 814s-819s.
109. Janku F, Kleibl Z, Novotny J, Tesarova P, Petruzelka L & Matous B 2004 Mammaglobin A, a novel marker of minimal residual disease in early stages breast cancer. Neoplasma 51 204-208.
110. Janni W, Hepp F, Rjosk D, Kentenich C, Strobl B, Schindlbeck C, Hantschmann P, Sommer H, Pantel K & Braun S 2001 The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence. Cancer 92 46-53.
111. Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S, Sommer H, Pantel K, Gerber B & Friese K 2005 The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer 103 884-891.
112. Jaramillo A, Narayanan K, Campbell LG, Benshoff ND, Lybarger L, Hansen TH, Fleming TP, Dietz JR & Mohanakumar T 2004 Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. Breast Cancer Research and Treatment 88 29-41.
113. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ & Thun MJ 2005 Cancer statistics. CA: A Cancer Journal for Clinicians 55 10-30.
114. Jiang Y, Harlocker SL, Molesh DA, Dillon DC, Stolk JA, Houghton RL, Repasky EA, Badaro R, Reed SG & Xu J 2002 Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays. Oncogene 21 2270-2282.
115. Jones C, Damiani S, Wells D, Chaggar R, Lakhani SR & Eusebi V 2001 Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast. American Journal of Pathology 158 207-214.
116. Jotsuka T, Okumura Y, Nakano S, Nitta H, Sato T, Miyachi M, Suzumura K & Yamashita J 2004 Persistent evidence of circulating tumor cells detected by means of RT-PCR for CEA mRNA predicts early relapse: a prospective study in node-negative breast cancer. Surgery 135 419-426.
117. Jung R, Petersen K, Kruger W, Wolf M, Wagener C, Zander A & Neumaier M 1999 Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable background transcription in granulocytes. British Journal of Cancer 81 870-873.
118. Kim DH, Yoon DS, Dooley WC, Nam ES, Ryu JW, Jung KC, Park HR, Sohn JH, Shin HS & Park YE 2003 Association of maspin expression with the high histological grade and lymphocyte-rich stroma in early-stage breast cancer. Histopathology 42 37-42.
119. Klein CA & Holzel D 2006 Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics. Cell Cycle 5 1788-1798.
120. Klein CA, Schmidt-Kittler O, Schardt JA, Pantel K, Speicher MR & Riethmuller G 1999 Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. PNAS 96 4494-4499.
121. Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH & Riethmuller G 2002 Genetic heterogeneity of single disseminated tumor cells in minimal residual cancer. Lancet 360 683-689.
122. Klug J, Beier HM, Bernard A, Chilton BS, Fleming TP, Lehrer RI, Miele L, Pattabiraman N & Singh G 2000 Uteroglobin/Clara cell 10-kDa family of proteins: nomenclature committee report. Annals of the New York Academy of Sciences 923 348-354.
123. Kwon S, Kang SH, Ro J, Jeon CH, Park JW & Lee ES 2005 The melanoma antigen gene as a surveillance marker for the detection of circulating tumor cells in patients with breast carcinoma. Cancer 104 251-256.
124. Lacroix M & Leclercq G 2004a Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Research and Treatment 83 249-289.
125. Lacroix M & Leclercq G 2004b An updated view on cell lines as in vitro models for breast tumors. In Focus on Breast Cancer Research, pp 131-182. Ed P Andrew. Yao. New York: Nova Science Publishers.
126. Lacroix M & Leclercq G 2004c About GATAS, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-alpha gene (ESR1) in breast cancer. Molecular and Cellular Endocrinology 219 1-7.
127. Lacroix M & Leclercq G 2005 The 'portrait' of hereditary breast cancer. Breast Cancer Research and Treatment 89 297-304.
128. Lacroix M & Leclercq G 2006 Hereditary breast cancer: an update on genotype and phenotype. In New Breast Cancer Research, pp 27-51. Ed P Andrew. Yao. New York: Nova Science Publishers.
129. Lacroix M, Zammatteo N, Remacle J & Leclercq G 2002 A low-density DNA microarray for analysis of markers in breast cancer. International Journal of Biological Markers 17 5-23.
130. Lacroix M, Toillon RA & Leclercq G 2004 Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics. Endocrine-Related Cancer 11 497-522.
131. Lacroix M, Toillon RA & Leclercq G 2006 P53 and breast cancer: an update. Endocrine-Related Cancer 13 293-325.
132. Landys K, Persson S, Kovarik J, Hultborn R & Holmberg E 1998 Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: results of a 20-year median follow-up. Breast Cancer Research and Treatment 49 27-33.
133. Latha K, Zhang W, Cella N, Shi HY & Zhang M 2005 Maspin mediates increased tumor cell apoptosis upon induction of the mitochondrial permeability transition. Molecular and Cellular Biology 25 1737-1748.
134. Leaf C 2004 Why we're losing the war on cancer and how to win it. Avastin, Erbitux, Gleevec. The new wonder drugs might make you think we're finally beating this dreaded scourge. We're not. Here's how to turn the fight around. Fortune 149 76-97.
135. Leclercq G, Lacroix M, Laïos I & Laurent G 2006 Estrogen receptor alpha: impact of ligands on intracellular shuttling and turnover rate in breast cancer cells. Current Cancer Drug Targets 6 39-64.
136. Lee HK, Hsu AK, Sajdak J, Qin J & Pavlidis P 2004 Coexpression analysis of human genes across many microarray data sets. Genome Research 14 1085-1094.
137. Lehrer RI, Xu G, Abduragimov A, Dinh NN, Qu XD, Martin D & Glasgow BJ 1998 Lipophilin, a novel heterodimeric protein of human tears. FEBS Letters 432 163-167.
138. Leitzel K, Lieu B, Curley E, Smith J, Chinchilli V, Rychlik W & Lipton A 1998 Detection of cancer cells in peripheral blood of breast cancer patients using reverse transcription-polymerase chain reaction for epidermal
139. Leone F, Perissinotto E, Viale A, Cavalloni G, Taraglio S, Capaldi A, Piacibello W, Torchio B & Aglietta M 2001 Detection of breast cancer cell contamination in leukopheresis product by real-time quantitative polymerase chain reaction. Bone Marrow Transplantation 27 517-523.
140. Ligtenberg MJ, Buijs F, Vos HL & Hilkens J 1992 Suppression of cell aggregation by high levels of episialin. Cancer Research 52 2318-2324.
141. Liotta LA & Stetler-Stevenson WG 1991 Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Research 51 5054s-5059s.
142. Liu Z, Kim J, Sypek JP, Wang IM, Horton H, Oppenheim FG & Bochner BS 2004 Gene expression profiles in human nasal polyp tissues studied by means of DNA microarray. Journal of Allergy and Clinical Immunology 114 783-790.
143. Liu S, Dontu G & Wicha MS 2005 Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Research 7 86-95.
144. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, Suri P & Wicha MS 2006 Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Research 66 6063-6071.
145. Lockett J, Yin S, Li X, Meng Y & Sheng S 2006 Tumor suppressive maspin and epithelial homeostasis. Journal of Cellular Biochemistry 97 651-660.
146. Loo LW, Grove DI, Williams EM, Neal CL, Cousens LA, Schubert EL, Holcomb IN, Massa HF, Glogovac J, Li CI et al. 2004 Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Research 64 8541-8549.
147. Loo WTY, Fong JHM, Zhu L, Cheung MNB & Chow LWC 2005 The value of bone marrow aspirates culture for the detection of bone marrow micrometastasis in breast cancer. Biomedicine and Pharmacotherapy 59 S384-S386.
148. Lopez-Guerrero JA, Gilabert PB, Gonzalez EB, Sanz Alonso MA, Perez JP, Talens AS, Oraval EA, de la Rubia Comos J & Boix SB 1999 Use of reverse-transcriptase polymerase chain reaction (RT-PCR) for carcinoembryonic antigen, cytokeratin 19, and maspin in the detection of tumor cells in leukopheresis products from patients with breast cancer: comparison with immunocytochemistry. Journal of Hematotherapy 8 53-61.
149. Luppi M, Morselli M, Bandieri E, Federico M, Marasca R, Barozzi P, Ferrari MG, Savarino M, Frassoldati A & Torelli G 1998 Sensitive detection of circulating breast cancer cells by reverse-transcriptase polymerase chain reaction of maspin gene. Annals of Oncology 7 619-624.
150. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF & Groom AC 1998 Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. American Journal of Pathology 153 865-873.
151. Maass N, Teffner M, Rosel F, Pawaresch R, Jonat W, Nagasaki K & Rudolph P 2001 Decline in the expression of the serine proteinase inhibitor maspin is associated with tumour progression in ductal carcinomas of the breast. Journal of Pathology 195 321-326.
152. Manhani AR, Manhani R, Soares HP, Bendit I, Lopes F, Nicoletti AG, Fonseca FL, Novaes M, Zatta SM, Arias V et al. 2001 CK-19 expression by RT-PCR in the peripheral blood of breast cancer patients correlates with response to chemotherapy. Breast Cancer Research and Treatment 66 249-254.
153. Manna PP, Jaramillo A, Majumder K, Campbell LG, Fleming TP, Dietz JR, Dipersio JF & Mohanakumar T 2003 Generation of CD8+ cytotoxic T lymphocytes against breast cancer cells by stimulation with mammaglobin-A-pulsed dendritic cells. Breast Cancer Research and Treatment 79 133-136.
154. Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U & Coombes RC 1999 Outcome of primary breast cancer patients with micrometastases: a long-term follow-up study. Lancet 354 197-202.
155. Marches R, Scheuermann R & Uhr J 2006 Cancer dormancy: from mice to man. Cell Cycle 5 1772-1778.
156. Martin KJ, Kritzman BM, Price LM, Koh B, Kwan CP, Zhang X, Mackay A, O'Hare MJ, Kaelin CM, Mutter GL et al. 2000 Linking gene expression patterns to therapeutic groups in breast cancer. Cancer Research 60 2232-2238.
157. Masuda TA, Kataoka A, Ohno S, Murakami S, Mimori K, Utsunomiya T, Inoue H, Tsutsui H, Kinoshita J, Masuda N et al. 2005 Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients. International Journal of Oncology 26 721-730.
158. Mazoujian G, Pinkus GS, Davis S & Haagensen DE Jr 1983 Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features. American Journal of Pathology 110 105-112.
159. Mehes G, Witt A, Kubista E & Ambros PF 2001 Circulating breast cancer cells are frequently apoptotic. American Journal of Pathology 159 17-20.
160. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C et al. 2004a HER-2 gene amplification can be acquired as breast cancer progresses. PNAS 101 9393-9398.
161. Mercatali L, Valenti V, Calistri D, Calpona S, Rosti G, Folli S, Gaudio M, Frassineti GL, Amadori D & Flamini E 2006 RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients. Annals of Oncology 17 424-428.
162. Mikhitarian K, Gillanders WE, Almeida JS, Martin RH, Varela JC, Metcalf JS, Cole DJ & Mitas M 2005a An innovative microarray strategy identifies informative molecular markers for the detection of micrometastatic breast cancer. Clinical Cancer Research 11 3697-3704.
163. Mikhitarian K, Martin RH, Mitas M, Mauldin PD, Palesch Y, Metcalf JS, Cole DJ & Gillanders WE 2005b Mims Study Group Molecular analysis improves sensitivity of breast sentinel lymph node biopsy: results of a multi-institutional prospective cohort study. Surgery 138 474-481.
164. Miksicek RJ, Myal Y, Watson PH, Walker C, Murphy LC & Leygue E 2002 Identification of a novel breast- and salivary gland-specific, mucin-like gene strongly expressed in normal and tumor human mammary epithelium. Cancer Research 62 2736-2740.
165. Min CJ, Tafra L & Verbanac KM 1998 Identification of superior markers for polymerase chain reaction detection of breast cancer metastases in sentinel lymph nodes. Cancer Research 58 4581-4584.
166. Mitas M, Mikhitarian K, Walters C, Baron PL, Elliott BM, Brothers TE, Robison JG, Metcalf JS, Palesch YY, Zhang Z et al. 2001 Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. International Journal of Cancer 93 162-171.
167. Mitas M, Mikhitarian K, Hoover L, Lockett MA, Kelley L, Hill A, Gillanders WE & Cole DJ 2002 Prostate-Specific Ets (PSE) factor: a novel marker for detection of metastatic breast cancer in axillary lymph nodes. British Journal of Cancer 86 899-904.
168. Mohsin SK, Zhang M, Clark GM & Craig Allred D 2003 Maspin expression in invasive breast cancer: association with other prognostic factors. Journal of Pathology 199 432-435.
169. Müller V & Pantel K 2005 BM micrometastases and circulating tumor cells in breast cancer patients: where have we been, where are we now and where does the future lie? Cytotherapy 7 478-482.
170. Müller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E, Marth C & Widschwendter M 2003 DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Research 63 7641-7645.
171. Müller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Janicke F & Pantel K 2005 Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clinical Cancer Research 11 3678-3685.
172. Murphy LC, Lee-Wing M, Goldenberg GJ & Shiu RP 1987 Expression of the gene encoding a prolactin-inducible protein by human breast cancers in vivo: correlation with steroid receptor status. Cancer Research 47 4160-4164.
173. Myal Y, Iwasiow B, Cosby H, Yarmill A, Blanchard A, Tsuyuki D, Fresnoza A, Duckworth ML & Shiu RPC 1998 Analysis of tissue- and hormone-specific regulation of the human prolactin-inducible proteidgross cystic disease fluid protein-1 5 gene in transgenic mice. Journal of Molecular Endocrinology 21 217-223.
174. Narayanan K, Jaramillo A, Benshoff ND, Campbell LG, Fleming TP, Dietz JR & Mohanakumar T 2004 Response of established human breast tumors to vaccination with mammaglobin-A cDNA. Journal of the National Cancer Institute 96 1388-1396.
175. Naumov GN, Townson JL, MacDonald IC, Wilson SM, Bramwell VH, Groom AC & Chambers AF 2003 Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Research and Treatment 82 199-206.
176. Naumov GN, Akslen LA & Folkman J 2006 Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 5 1779-1787.
177. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L et al. 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clinical Cancer Research 10 5367-5374.
178. Nissan A, Jager D, Roystacher M, Prus D, Peretz T, Eisenberg I, Freund HR, Scanlan M, Ritter G, Old LJ et al. 2006 Multimarker RT-PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients. British Journal of Cancer 94 681-685.
179. Núñez-Villar MJ, Martinez-Arribas F, Pollan M, Lucas AR, Sanchez J, Tejerina A & Schneider J 2003 Elevated mammaglobin (h-MAM) expression in breast cancer is associated with clinical and biological features defining a less aggressive tumour phenotype. Breast Cancer Research 5 R65-R70.
180. O'Brien N, Maguire TM, O'Donovan N, Lynch N, Hill AD, McDermott E, O'Higgins N & Duffy MJ 2002 Mammaglobin a: a promising marker for breast cancer. Clinical Chemistry 48 1362-1364.
181. O'Brien N, O'Donovan N, Hill AD, McDermott E, O'Higgins N & Duffy MJ 2003 B726P, a gene expressed specifically in breast tissue. Proceedings of the American Association of Cancer Research 32 63.
182. O'Brien N, O'Donovan N, Ryan B, Hill AD, McDermott E, O'Higgins N & Duffy MJ 2005 Mammaglobin A in breast cancer: existence of multiple molecular forms. International Journal of Cancer 114 623-627.
183. Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsak U, Boltax J, Grall F, Dube A, Weiss A, Brown L et al. 2000 PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. Journal of Biological Chemistry 275 1216-1225.
184. Ouellette RJ, Richard D & Maicas E 2004 RT-PCR for mammaglobin genes, MGBl and MGB2, identifies breast cancer micrometastasis in sentinel lymph nodes. American Journal of Clinical Pathology 121 637-643.
185. Pachmann K, Camara O, Kavallaris A, Schneider U, Schünemann S & Höffken K 2005 Quantification of the response of circulating epithelial cells to neoadjuvant treatment for breast cancer: a new tool for therapy monitoring. Breast Cancer Research 7 R975-R979.
186. Pantel K & Brakenhoff RH 2004 Dissecting the metastatic cascade. Nature Reviews Cancer 4 448-456.
187. Pantel K & Woelfle U 2005 Detection and molecular characterisation of disseminated tumour cells: implications for anti-cancer therapy. Biochimica et Biophysica Acta 1756 53-64.
188. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR & Riethmuller G 1993 Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. Journal of the National Cancer Institute 85 1419-1424.
189. Pantel K, Cote RJ & Fodstad O 1999 Detection and clinical importance of micrometastatic disease. Journal of the National Cancer Institute 91 1113-1124.
190. Pemberton PA, Tipton AR, Pavloff N, Smith J, Erickson JR, Mouchabeck ZM & Kiefer MC 1997 Maspin is an intracellular serpin that partitions into secretory vesicles and is present at the cell surface. Journal of Histochemistry and Cytochemistry 45 1697-1706.
191. Pierga JY, Bonneton C, Vincent-Salomon A, de Cremoux P, Nos C, Blin N, Pouillart P, Thiery JP & Magdelénat H 2004 Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clinical Cancer Research 10 1392-1400.
192. Pierga JY, Bonneton C, Magdelenat H, Vincent-Salomon A, Nos C, Boudou E, Pouillart P, Thiery JP & de Cremoux P 2005 Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients. International Journal of Cancer 114 291-298.
193. Polyak K & Hu M 2005 Do myoepithelial cells hold the key for breast tumor progression? Journal of Mammary Gland Biology and Neoplasia 10 231-247.
194. Poulsom R, Hanby AM, Lalani EN, Hauser F, Hoffmann W & Stamp GW 1997 Intestinal trefoil factor (TFF 3) and pS2 (TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium. Journal of Pathology 183 30-38.
195. Quintela-Fandino M, Lopez JM, Hitt R, Gamarra S, Jimeno A, Ayala R, Hornedo J, Guzman C, Gilsanz F & Cortes-Funes H 2006 Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support. Journal of Clinical Oncology 24 3611-3618.
196. Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, Robertson JF & Ellis IO 2005 Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Modern Pathology 18 1295-1304.
197. Ranganathan AC, Adam AP & Aguirre-Ghiso JA 2006 Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy. Cell Cycle 5 1799-1807.
198. Reinholz MM, Nibbe A, Jonart LM, Kitzmann K, Suman VJ, Ingle JN, Houghton R, Zehentner B, Roche PC & Lingle WL 2005 Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer. Clinical Cancer Research 11 3722-3732.
199. Ring A, Smith IE & Dowsett M 2004 Circulating tumour cells in breast cancer. Lancet Oncology 5 79-88.
200. Ring AE, Zabaglo L, Ormerod MG, Smith IE & Dowsett M 2005 Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. British Journal of Cancer 92 906-912.
201. Roetger A, Merschjann A, Dittmar T, Jackisch C, Barnekow A & Brandt B 1998 Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model. American Journal of Pathology 153 1797-1806.
202. Roncella S, Ferro P, Bacigalupo B, Dessanti P, Giannico A, Gorji N, Moroni M, Tozzini S, Pensa F, Gianquinto D et al. 2006 Relationship between human mammaglobin mRNA expression in breast cancer tissue and clinicopathologic features of the tumors. Journal of Experimental and Clinical Cancer Research 25 65-72.
203. Ross DT & Perou CM 2001 A comparison of gene expression signatures from breast tumors and breast tissue derived cell lines. Disease Markers 17 99-109.
204. Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N, Tallman MS, Kennedy MJ, Davidson NE, Sweet D et al. 1993 Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82 2605-2610.
205. Ruud P, Fodstad O & Hovig E 1999 Identification of a novel cytokeratin 19 pseudogene that may interfere with reverse transcriptase- polymerase chain reaction assays used to detect micrometastatic tumor cells. International Journal of Cancer 80 119-125.
206. Savtchenko ES, Schiff TA, Jiang CK, Freedberg IM & Blumenberg M 1988 Embryonic expression of the human 40-kD keratin: evidence from a processed pseudogene sequence. American Journal of Human Genetics 43 630-637.
207. Schardt JA, Meyer M, Hartmann CH, Schubert F, Schmidt-Kittler O, Fuhrmann C, Polzer B, Petronio M, Eils R & Klein CA 2005 Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 8 227-239.
208. Schindlbeck C, Janni W, Shabani N, Rack B, Gerber B, Schmitt M, Harbeck N, Sommer H, Braun S & Friese K 2004 Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrow. Breast Cancer Research and Treatment 87 65-74.
209. Schindlbeck C, Jeschke U, Schulze S, Karsten U, Janni W, Rack B, Sommer H & Friese K 2005 Characterization of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen-Friedenreich tumor antigen. Histochemistry and Cell Biology 123 631-637.
210. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P et al. 2003 From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. PNAS 100 7737-7742.
211. Shi HY, Zhang W, Liang R, Abraham S, Kittrell FS, Medina D & Zhang M 2001 Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model. Cancer Research 61 6945-6951.
212. Sidransky D 1997 Nucleic acid-based methods for the detection of cancer. Science 278 1054-1059.
213. Silva AL, Diamond J, Silva MR & Passas-Coelho JL 2001a Cytokeratin 20 is not a reliable molecular marker for occult breast cancer cell detection in haematological tissues. Breast Cancer Research and Treatment 66 59-66.
214. Silva JM, Dominguez G, Silva J, Garcia JM, Sanchez A, Rodriguez O, Provencio M, Espana P & Bonilla F 2001b Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clinical Cancer Research 7 2821-2825.
215. Silva JM, Garcia JM, Dominguez G, Silva J, Miralles C, Cantos B, Coca S, Provencio M, Espana P & Bonilla F 2002 Persistence of tumor DNA in plasma of breast cancer patients after mastectomy. Annals of Surgical Oncology 9 71-76.
216. Silva HA, Abraul E, Raimundo D, Dias MF, Marques C, Guerra C, de Oliveira CF & Regateiro FJ 2006 Molecular detection of EGFRvIII-positive cells in the peripheral blood of breast cancer patients. European Journal of Cancer 42 2617-2622.
217. Siwek B, Larsimont D, Lacroix M & Body JJ 1998 Establishment and characterization of three new breast-cancer cell lines. International Journal of Cancer 76 677-683.
218. Sjodin A, Guo D, Lund-Johansen M, Krossnes BK, Lilleng P, Henriksson R & Hedman H 2005 Secretoglobins in the human pituitary: high expression of lipophilin B and its down-regulation in pituitary adenomas. Acta Neuropathologica 109 381-386.
219. Slade MJ, Singh A, Smith BM, Tripuraneni G, Hall E, Peckitt C, Fox S, Graham H, Luchtenborg M, Sinnett HD et al. 2005 Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years. International Journal of Cancer 114 94-100.
220. Smerage JB & Hayes DF 2006 The measurement and therapeutic implications of circulating tumour cells in breast cancer. British Journal of Cancer 94 8-12.
221. Smirnov DA, Zweitzig DR, Foulk BW, Miller MC, Doyle GV, Pienta KJ, Meropol NJ, Weiner LM, Cohen SJ, Moreno JG et al. 2005 Global gene expression profiling of circulating tumor cells. Cancer Research 65 4993-4997.
222. Smith BM, Slade MJ, English J, Graham H, Luchtenborg M, Sinnett HD, Cross NC & Coombes RC 2000 Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. Journal of Clinical Oncology 18 1432-1439.
223. Solakoglu O, Maierhofer C, Lahr G, Breit E, Scheunemann P, Heumos I, Pichlmeier U, Schlimok G, Oberneder R, Kollermann MW et al. 2002 Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. PNAS 99 2246-2251.
224. Solomayer EF, Feuerer M, Bai L, Umansky V, Beckhove P, Meyberg GC, Bastert G, Schirrmacher V & Diel IJ 2003 Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer. Clinical Cancer Research 9 174-180.
225. Solomayer EF, Becker S, Pergola-Becker G, Bachmann R, Kramer B, Vogel U, Neubauer H, Wallwiener D, Huober J & Fehm TN 2006 Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Research and Treatment 98 179-184.
226. Sopel M, Kasprzyk I & Berdowska I 2005 Maspin and c-erbB-2 expression in correlation with microvessel density in invasive ductal breast cancer. Folia Histochemica et Cytobiologica 43 109-116.
227. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S et al. 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS 100 8418-8423.
228. Span PN, Waanders E, Manders P, Heuvel JJ, Foekens JA, Watson MA, Beex LV & Sweep FC 2004 Mammaglobin is associated with low-grade steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time. Journal of Clinical Oncology 22 691-698.
229. Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis Ch, Apostolaki S, Malamos N, Kakolyris S, Kotsakis A, Xenidis N et al. 2002 Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. Journal of Clinical Oncology 20 3404-3412.
230. Stathopoulos EN, Sanidas E, Kafousi M, Mavroudis D, Askoxylakis J, Bozionelou V, Perraki M, Tsiftsis D & Georgoulias V 2005 Detection of CK-19 mRNA positive cells in peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillarylymph nodes. Annals of Oncology 16 240-246.
231. Sternlicht MD, Kedeshian P, Shao ZM, Safarians S & Barsky SH 1997 The human myoepithelial cell is a natural tumor suppressor. Clinical Cancer Research 3 1949-1958.
232. Stoeckelhuber M, Messmer EM, Schmidt C, Xiao F, Schubert C & Klug J 2006 Immunohistochemical analysis of secretoglobin SCGB 2A1 expression in human ocular glands and tissues. Histochemistry and Cell Biology 126 103-109.
233. Sugita Y, Wada H, Fujita S, Nakata T, Sato S, Noguchi Y, Jungbluth AA, Yamaguchi M, Chen YT, Stockert E et al. 2004 NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Research 64 2199-2204.
234. Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rouzier R, Dunmire V, Stec J, Valero V, Sneige N, Albarracin C et al. 2005 A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocrine-Related Cancer 12 1059-1069.
235. Taback B, Chan AD, Kuo CT, Bostick PJ, Wang HJ, Giuliano AE & Hoon DS 2001 Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. Cancer Research 61 8845-8850.
236. Tian W, Osawa M, Horiuchi H & Tomita Y 2004 Expression of the prolactin-inducible protein (PIP/GCDFP15) gene in benign epithelium and adenocarcinoma of the prostate. Cancer Science 95 491-495.
237. Tothill RW, Kowalczyk A, Rischin D, Bousloutas A, Haviv I, van Laar RK, Waring PM, Zalcberg J, Ward R, Biankin AV et al. 2005 An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Research 65 4031-4040.
238. Townson JL & Chambers AF 2006 Dormancy of solitary metastatic cells. Cell Cycle 5 1744-1750.
239. Trocciola SM, Hoda S, Osborne MP, Christos PJ, Levin H, Martins D, Carson J, Daly J & Simmons RM 2005 Do bone marrow micrometastases correlate with sentinel lymph node metastases in breast cancer patients? Journal of the American College of Surgeons 200 720-725.
240. Umekita Y & Yoshida H 2003 Expression of maspin is up-regulated during the progression of mammary ductal carcinoma. Histopathology 42 541-545.
241. Umekita Y, Ohi Y, Sagara Y & Yoshida H 2002 Expression of maspin predicts poor prognosis in breast-cancer patients. International Journal of Cancer 100 452-455.
242. Valgussa P, Bonadonna G & Veronesi U 1978 Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer 41 1170-1178.
243. Varga Z, Theurillat JP, Filonenko V, Sasse B, Odermatt B, Jungbluth AA, Chen YT, Old LJ, Knuth A, Jager D et al. 2006 Preferential nuclear and cytoplasmic NY-BR-1 protein expression in primary breast cancer and lymph node metastases. Clinical Cancer Research 12 2745-2751.
244. Viehl CT, Tanaka Y, Chen T, Frey DM, Tran A, Fleming TP, Eberlein TJ & Goedegebuure PS 2005 Tat mammaglobin fusion protein transduced dendritic cells stimulate mammaglobin-specific CD4 and CD8 T cells. Breast Cancer Research and Treatment 91 271-278.
245. Wang W, Epler J, Salazar LG & Riddell SR 2006 Recognition of breast cancer cells by CD8 + cytotoxic T-Cell clones specific for NY-BR-1. Cancer Research 66 6826-6833.
246. Watson MA & Fleming TP 1996 Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Research 56 860-865.
247. Watson MA, Dintzis S, Darrow CM, Voss LE, DiPersio J, Jensen R & Fleming TP 1999 Mammaglobin expression in primary, metastatic, and occult breast cancer. Cancer Research 59 3028-3031.
248. Weigelt B, Verduijn P, Bosma AJ, Rutgers EJ, Peterse HL & van't Veer LJ 2004 Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers. British Journal of Cancer 90 1531-1537.
249. Weigelt B, Hu Z, He X, Livasy C, Carey LA, Ewend MG, Glas AM, Perou CM & Van't Veer LJ 2005 Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Research 65 9155-9158.
250. Weinschenker P, Soares HP, Clark O & Giglio AD 2004 Immunocytochemical detection of epithelial cells in the bone marrow of primary breast cancer patients: a meta-analysis. Breast Cancer Research and Treatment 87 215-224.
251. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, Ward RL, Hawkins NJ, Quinn DI, Russell PJ et al. 2003 Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. PNAS 100 3410-3415.
252. White DE, Rayment JH & Muller WJ 2006 Addressing the role of cell adhesion in tumor cell dormancy. Cell Cycle 5 1756-1759.
253. Wicha MS, Liu S & Dontu G 2006 Cancer stem cells: an old idea - a paradigm shift. Cancer Research 66 1883-1890.
254. Wiedswang G, Borgen E, Karesen R, Kvalheim G, Nesland JM, Qvist H, Schlichting E, Sauer T, Janbu J, Harbitz T et al. 2003 Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. Journal of Clinical Oncology 21 3469-3478.
255. Wiedswang G, Borgen E, Karesen R, Qvist H, Janbu J, Kvalheim G, Nesl JM & Naume B 2004 Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clinical Cancer Research 10 5342-5348.
256. Wiedswang G, Borgen E, Schirmer C, Karesen R, Kvalheim G, Nesland JM & Naume B 2006 Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer. International Journal of Cancer 118 2013-2019.
257. Wülfing P, Borchard J, Bürger H, Heidl S, Zänker KS, Kiesel L & Brandt B 2006 HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clinical Cancer Research 12 1715-1720.
258. Xenidis N, Vlachonikolis I, Mavroudis D, Perraki M, Stathopoulou A, Malamos N, Kouroussis C, Kakolyris S, Apostolaki S, Vardakis N et al. 2003 Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Annals of Oncology 14 849-855.
259. Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, Kalbakis K, Androulakis N, Kouroussis C, Pallis T et al. 2006 Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. Journal of Clinical Oncology 24 3756-3762.
260. Xiao F, Mirwald A, Papaioannou M, Baniahmad A & Klug J 2005 Secretoglobin 2A1 is under selective androgen control mediated by a peculiar binding site for Sp family transcription factors. Molecular Endocrinology 19 2964-2978.
261. Zach O & Lutz D 2006 Tumor cell detection in peripheral blood and bone marrow. Current Opinion in Oncology 18 48-56.
262. Zafrakas M, Petschke B, Donner A, Fritzsche F, Kristiansen G, Knuechel R & Dahl E 2006a Expression analysis of mammaglobin A (SCGB2A2) and Lipophilin B (SCGB1D2) in more than 300 human tumors and matching normal tissues rveals their co-expression in gynaecological malignancies. BMC Cancer 6 88.
263. Zafrakas M, Chorovicer M, Klaman I, Kristiansen G, Wild PJ, Heindrichs U, Knüchel R & Dahl E 2006b Systematic characterisation of GABRP expression in sporadic breast cancer and normal breast tissue. International Journal of Cancer 118 1453-1459.
264. Zehentner BK 2002a Detection of disseminated tumor cells: strategies and diagnostic implications. Expert Reviews in Molecular Diagnostic 2 89-96.
265. Zehentner BK, Dillon DC, Jiang Y, Xu J, Bennington A, Molesh DA, Zhang X, Reed SG, Persing D & Houghton RL 2002b Application of a multigene reverse transcription-PCR assay for detection of mammaglobin and complementary transcribed genes in breast cancer lymph nodes. Clinical Chemistry 48 1225-1231.
266. Zehentner BK, Persing DH, Deme A, Toure P, Hawes SE, Brooks L, Feng Q, Hayes DC, Critichlow CW, Houghton RL & Kiviat NB 2004 Mammaglobin as a Novel Breast Cancer Biomarker: Multigene Reverse Transcription-PCR Assay and Sandwich ELISA. Clinical Chemistry 50 2069-2076.
267. Zhang W & Zhang M 2002 Tissue microarray analysis of maspin expression and its reverse correlation with mutant p53 in various tumors. International Journal of Oncology 20 1145-1150.
268. Zhang M, Volpert O, Shi YH & Bouck N 2000 Maspin is an angiogenesis inhibitor. Nature Medicine 6 196-199.
269. Zhong XY, Kaul S, Eichler A & Bastert G 1999 Evaluating GA733-2 mRNA as a marker for the detection of micrometastatic breast cancer in peripheral blood and bone marrow. Archives of Gynecology and Obstetrics 263 2-6.
270. Zhu L, Loo WT & Chow LW 2005 Circulating tumor cells in patients with breast cancer: possible predictor of micrometastasis in bone marrow but not in sentinel lymph nodes. Biomedicine and Pharmacotherapy 59 S355-S358.
271. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C & Hadary A 2005 Comparison of HER2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. British Journal of Cancer 93 552-556.
272. Zieglschmid V, Hollmann C & Böcher O 2005 Detection of disseminated tumor cells in peripheral blood. Critical Reviews in Clinical Laboratory Sciences 42 155-196.
273. Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S, Rafidi K, Seftor E & Sager R 1994 Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263 526-529.